Chagas Disease — Cardiovascular Manifestations

• Direct myocardial parasitism and tissue destruction: T. cruzi directly invades cardiac myocytes, leading to chronic inflammation and progressive myocyte loss. The parasite replicates intracellularly within the cytoplasm and can lyse infected cells, creating inflammatory foci. Over decades, this results in diffuse myocardial necrosis, fibrosis, and replacement of functional myocardium with fibrous tissue, predominantly affecting the apex and posterior walls.

• Autoimmune cross-reactivity and molecular mimicry: Chronic antigenic stimulation from persistent parasites triggers an abnormal CD8+ T-cell and B-cell response that cross-reacts with cardiac myosin, tropomyosin, and other myocardial proteins. This autoimmune cardiomyopathy component perpetuates inflammation even after parasitemia is undetectable, driven by molecular mimicry between parasite epitopes and cardiac antigens. IgG antibodies against cardiac proteins deposit in myocardium, activating complement and further amplifying tissue injury.

• Sympathetic denervation and neuronal destruction: T. cruzi selectively destroys parasympathetic (cholinergic) neurons in the cardiac plexus and conduction system, leading to unopposed sympathetic activity. This denervation is particularly prominent in the right ventricle and conduction pathways. Loss of vagal tone results in resting tachycardia, increased myocardial oxygen demand, and arrhythmogenesis. The destruction of Auerbach's and Meissner's plexuses in the GI tract explains the association with megacolon and megaesophagus.

• Chronic inflammatory state and fibrosis: Persistent low-grade parasitemia maintains a pro-inflammatory milieu with elevated TNF-α, IL-6, and transforming growth factor-β (TGF-β). This promotes excessive collagen deposition, myocardial stiffness, and progressive diastolic and systolic dysfunction. Myocardial inflammation is enhanced by tissue factor expression and activation of coagulation cascades, predisposing to thromboembolism.

• Autonomic dysfunction and arrhythmogenesis: Beyond neuronal destruction, T. cruzi induces abnormalities in calcium handling, gap junction remodeling, and electrical heterogeneity. Fibrosis creates areas of slow conduction and reentry substrates. The combination of denervation, inflammation, and structural remodeling generates a highly arrhythmogenic substrate prone to both atrial and ventricular dysrhythmias.

• ***Trypanosoma cruzi* infection**: The obligatory cause of Chagas disease. Acute infection in 30–50% of immunocompetent individuals remains asymptomatic or minimally symptomatic. Progression to chronic cardiomyopathy occurs in 20–30% of chronically infected persons over 10–30 years.

• Parasite strain and genetic factors: The T. cruzi strain (TcI-VI discrete typing units) influences disease severity, with TcII associated with more severe cardiomyopathy in the Southern Cone. Host genetic polymorphisms in genes encoding inflammatory cytokines (IL-6, TNF-α), chemokine receptors (CCR5), and cardiac troponins modify disease expression and progression.

• Duration and intensity of infection: Longer duration of chronic infection correlates with greater myocardial damage. Higher parasitemia levels during acute phase and persistent parasitemia in chronic phase predict progression to cardiomyopathy.

• Immunosuppression: Solid organ transplant recipients and patients with HIV/AIDS (CD4 <200 cells/μL) are at dramatically increased risk for acute reactivation and rapidly progressive cardiomyopathy, sometimes presenting as acute myocarditis with cardiogenic shock.

• Nonspecific fever, malaise, hepatosplenomegaly
• Romaña's sign: Unilateral periorbital edema and conjunctivitis if inoculation site is near the eye
• Chagoma: Erythematous, indurated papule at the inoculation site
• Myocarditis with chest pain, palpitations, dyspnea (rare)
• Fulminant myocarditis and cardiogenic shock (very rare, more common in immunocompromised hosts)

• Majority of patients remain asymptomatic for years despite serologic evidence of infection
• Incidental finding of abnormal ECG (most commonly right axis deviation, right anterior fascicular block [RAFB], or first-degree AV block)
• Normal ejection fraction and normal cardiac imaging

• Progressive dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea (signs of dilated cardiomyopathy)
• Palpitations and syncope/presyncope from ventricular arrhythmias (distinguishing feature compared to other causes of DCM)
• Sudden cardiac death: Prominent feature; accounts for significant mortality
• Fatigue, exercise intolerance
• Chest pain (may resemble angina)
• Right heart failure signs: peripheral edema, jugular venous distention, hepatomegaly

Physical Examination Findings

• Displaced apical impulse (dilated cardiomyopathy)
• S3 gallop (dilated ventricle with reduced ejection fraction)
• Mitral regurgitation murmur (secondary to left ventricular dilation and papillary muscle dysfunction)
• Atrial fibrillation with irregular pulse
• Signs of biventricular heart failure
• Hepatomegaly and ascites in advanced disease

• Two positive serologic tests from different methodologies (required for diagnosis of chronic Chagas disease)
• Enzyme immunoassay (ELISA): 95–98% sensitivity/specificity; most widely available
• Indirect immunofluorescence assay (IFA): High specificity; reference standard
• Radioimmunoprecipitation assay (RIPA): Gold standard for confirmation; limited availability
• Western blot: High specificity, used as confirmatory test
• Low parasitemia in chronic phase: Blood smear and culture rarely positive; direct detection not useful for diagnosis in chronic disease

• Right axis deviation: Most common abnormality; seen in 50–60% of Chagas cardiomyopathy
• Right anterior fascicular block (RAFB): Highly specific (~95%) for Chagas disease among causes of right axis deviation; left axis superior, rsR' pattern in lead aVL
• First-degree AV block: Reflects parasympathetic denervation
• Atrial fibrillation: Indicates advanced disease
• Premature ventricular contractions: Frequent, often multifocal
• Ventricular tachycardia: Characteristic finding; may be polymorphic or monomorphic
• Prolonged QTc interval
• Low voltage QRS (in advanced disease with extensive fibrosis)
• Apical aneurysm pattern: Q waves in precordial leads without reciprocal ST elevation (pathognomonic when present)

Echocardiography

• Dilated cardiomyopathy pattern: Enlarged left ventricle (LV end-diastolic diameter >55 mm), reduced ejection fraction (<40%)
• Apical akinesia or dyskinesia: Characteristic regional wall motion abnormality; apical "ballooning" or aneurysm formation (distinguishes from other cardiomyopathies)
• Reduced longitudinal strain on speckle-tracking imaging
• Secondary mitral regurgitation (functional, due to annular dilation)
• Biventricular dilation in advanced cases
• Right ventricular dysfunction
• Thrombus: LV apical thrombus present in 5–10% of patients with apical aneurysm

• Characteristic late gadolinium enhancement (LGE) pattern: Subepicardial or mid-wall fibrosis, particularly at the apex and inferior wall
• Apical thinning and aneurysm formation
• Helps differentiate from other causes of cardiomyopathy
• LGE burden correlates with arrhythmia risk

Chest X-ray

• Cardiomegaly with cardiothoracic ratio >50%
• Pulmonary edema (if decompensated)
• May show megacolon or megaesophagus (findings in advanced disease)

Cardiac Biomarkers

• Troponin elevation: May be present during acute myocarditis phase or acute decompensation
• BNP/NT-proBNP: Elevated in symptomatic cardiomyopathy; reflects cardiac stretch and dysfunction

Holter Monitor/Event Monitor

• Frequently demonstrates frequent PVCs, runs of nonsustained ventricular tachycardia, and atrial arrhythmias
• Critical for risk stratification; burden of ectopy correlates with SCD risk

• Confirmed T. cruzi serology (≥2 positive tests by different methods) PLUS
• Evidence of cardiac involvement (any of the following):
• Symptoms/signs consistent with cardiomyopathy
• Echocardiographic evidence of LV dysfunction (EF <45%)
• Characteristic ECG abnormalities (RAFB, apical Q waves, frequent PVCs, sustained VT)
• Cardiac imaging evidence of apical aneurysm or characteristic LGE on MRI

Antiparasitic Therapy

• Benznidazole (first-line in acute phase and early chronic phase):
• Dosing: 5–7 mg/kg/day divided into 2–3 doses for 60 days
• Mechanism: Produces reactive intermediates that damage parasite DNA; efficacy ~60–90% at clearing parasitemia in acute phase
• Evidence for cardiac benefit in early indeterminate chronic phase (preserved EF, minimal ECG changes) is modest; recent trials (BENEFIT trial) showed marginal benefit in advanced chronic cardiomyopathy
• Adverse effects: Peripheral neuropathy (8–10%), rash, gastrointestinal disturbance, agranulocytosis (rare but serious)
• Monitor: CBC, liver function tests; baseline neurologic exam

• Nifurtimox (alternative if benznidazole contraindicated):
• Dosing: 8–10 mg/kg/day divided into 3–4 doses for 90 days
• Less commonly used in chronic phase due to poorer tolerability
• Adverse effects: GI distress, neuropsychiatric effects (insomnia, anxiety, tremor), peripheral neuropathy

• Current recommendations: Consider antiparasitic therapy in:
• All acute phase infections
• Early indeterminate chronic phase (asymptomatic, normal EF, minimal ECG changes)
• Pregnant women
• Immunocompromised patients
• Patients awaiting organ transplant
• Established cardiomyopathy with reduced EF: Antiparasitic benefit unclear; requires individualized risk-benefit assessment

• ACE inhibitors/ARBs: First-line; reduce afterload, slow LV remodeling, prevent progression
• Lisinopril, enalapril, losartan
• Target: Maximum tolerated dose

• Beta-blockers: Essential for symptomatic patients and arrhythmia control
• Metoprolol succinate ER, carvedilol, bisoprolol
• Start low, titrate to target or maximum tolerated dose
• Particularly important given sympathetic denervation

• Aldosterone antagonists: Indicated in reduced EF or signs of HF
• Spironolactone or eplerenone
• Monitor K+ and renal function

• SGLT2 inhibitors: Emerging evidence for benefit in cardiomyopathy regardless of diabetes status
• Dapagliflozin, empagliflozin

• Diuretics: For volume overload
• Loop diuretics (furosemide) if pulmonary/peripheral edema present
• Titrate to euvolemia

• Ivabradine: Consider if sinus tachycardia present despite beta-blockade (heart rate-lowering effect may reduce myocardial oxygen demand in denervated heart)

Arrhythmia Management

• Ventricular arrhythmias (characteristic of Chagas cardiomyopathy):
• Beta-blockers as first-line antiarrhythmic (sympathetic denervation makes additional sympathomimetics harmful)
• Amiodarone: Most effective antiarrhythmic in Chagas disease; preferred for sustained VT
• Dosing: Loading 600–800 mg daily for 7–10 days, then maintenance 200–400 mg daily
• Baseline and periodic: TSH, LFTs, ophthalmologic exam
• Sotalol or dofetilide: Alternative Class III agents (require caution with QT prolongation)
• Avoid Class I antiarrhythmics (flecainide, procainamide) and positive inotropes when possible due to increased proarrhythmia risk

• Implantable cardioverter-defibrillator (ICD):
• Primary prevention ICD indicated if:
• EF ≤35% despite optimal medical therapy (similar to ischemic cardiomyopathy guidelines)
• Significant non-sustained VT on monitoring with inducible VT on electrophysiology study
• However, Chagas patients may have higher arrhythmia burden at lower EF thresholds, and some experts consider ICD at EF 40–50% if high-risk features present
• Secondary prevention ICD for survivors of sustained VT/VF
• CRT-ICD for patients with EF ≤35% and QRS ≥120 ms (though Chagas may have narrower QRS with RAFB)

• Atrial fibrillation:
• Rate control with beta-blockers or calcium channel blockers (diltiazem, verapamil)
• Anticoagulation: Indicated for AF; use direct oral anticoagulants (DOACs) or warfarin per standard guidelines
• Rhythm control with amiodarone if needed
• Catheter ablation: Limited experience in Chagas disease but may be considered for symptomatic AF refractory to antiarrhythmics

Thromboembolism Prevention

• Anticoagulation indicated if:
• Atrial fibrillation present
• LV thrombus detected on imaging (even in sinus rhythm)
• EF severely reduced with dilated cardiomyopathy and stasis
• History of thromboembolism
• Agents: DOACs (apixaban, dabigatran, rivaroxaban, edoxaban) preferred over warfarin unless contraindicated

Cardiac Transplantation

• Consideration for end-stage Chagas cardiomyopathy refractory to optimal medical therapy
• Challenging outcomes due to:
• High recurrence of cardiac disease in allograft if recipient remains infected
• Immunosuppression may lead to acute reactivation

Cardiac emergencies

• Sudden cardiac death (emergency): The most feared complication; scar-related reentry around apical/inferolateral fibrosis degenerates into ventricular fibrillation or pulseless ventricular tachycardia. Signaled by exertional syncope, sustained monomorphic VT, or high-burden nonsustained VT on Holter. Managed by ACLS defibrillation, then ICD evaluation per the ACC/AHA/HRS ventricular arrhythmia and sudden death guideline.
• Complete AV block / symptomatic sinus node dysfunction (emergency): Fibrotic destruction of the conduction axis plus parasympathetic denervation produces progressive block. Signaled by syncope with bradycardia or a wide-complex escape rhythm; requires temporary then permanent pacing per the ACC/AHA/HRS bradycardia guideline.
• Cardioembolic stroke and systemic embolism (emergency): Stasis in an akinetic apical aneurysm plus a prothrombotic inflammatory state; signaled by abrupt focal deficit or limb/mesenteric ischemia, with apical thrombus on echocardiography.
• Cardiogenic shock from decompensated HFrEF (emergency): End-stage biventricular fibrosis; signaled by hypotension, rising lactate, cool extremities, and worsening renal function.
• Reactivation disease in immunosuppression (emergency): Loss of T-cell control after transplant or in advanced HIV yields acute myocarditis, or meningoencephalitis/brain mass lesions; signaled by detectable parasitemia on smear or PCR, new arrhythmia, or new neurologic deficits.

Chronic and extracardiac complications

• Atrial fibrillation: Atrial fibrosis and dilation; brings rate-related decompensation and stroke risk.
• Megaesophagus / megacolon: Enteric plexus destruction; signaled by dysphagia with regurgitation or refractory constipation, and complicated by aspiration pneumonia or sigmoid volvulus (surgical emergency).
• Congenital transmission: Vertical spread from an untreated woman; CDC recommends testing infants of seropositive mothers.

Treatment-related complications

• Benznidazole: Dose-limiting dermatologic hypersensitivity (including severe exfoliative reactions), dose-dependent peripheral neuropathy, and rare bone marrow suppression/agranulocytosis — signaled by rash, paresthesias, or neutropenia on serial CBC.
• Nifurtimox: Anorexia with weight loss and neuropsychiatric effects; poor tolerability limits completion.
• Amiodarone: Thyroid dysfunction, hepatotoxicity, and pulmonary fibrosis — signaled by abnormal TSH/LFTs or new dyspnea with reduced diffusing capacity.
• Post-transplant immunosuppression: Provokes reactivation, so protocols include serial parasitologic/PCR surveillance.

• Best next step depends on phase: In suspected acute infection, look for the parasite — trypomastigotes on peripheral blood smear (or PCR); antibodies have not yet formed. In the chronic phase, order serology, and confirm with a second assay using a different antigen/method, as CDC recommends. Choosing serology for acute disease (or a smear for chronic disease) is the classic wrong answer.
• The ECG signature examiners want: a conduction disturbance combining right bundle branch block with left anterior fascicular block, often with frequent multiform PVCs — in a patient from Latin America with a dilated heart, this pairing is the giveaway.
• Apical aneurysm with precordial Q waves is the anatomic buzzword: a thin, akinetic apex with normal coronaries. Do not label it prior myocardial infarction — that is the intended distractor. Echocardiography looking for apical thrombus follows, since thrombus mandates anticoagulation.
• Arrhythmia out of proportion to ejection fraction distinguishes Chagas from most other dilated cardiomyopathies: syncope and sustained VT can precede severe systolic dysfunction, so syncope in a Chagas patient is a red flag for VT, not vasovagal.
• The one association tested: the same autonomic-plexus destruction that causes cardiomyopathy causes megaesophagus (achalasia-like dysphagia) and megacolon — a cardiac plus GI stem is nearly diagnostic.
• Antiparasitic therapy is not heart failure therapy: benznidazole (or nifurtimox) clears parasitemia and is most valuable in acute, congenital, reactivated, and early indeterminate disease; in established cardiomyopathy it does not reverse fibrosis. Guideline-directed HFrEF therapy — ARNI (or ACEI/ARB), beta blocker, MRA, and SGLT2 inhibitor, per the AHA/ACC/HFSA heart failure guideline — plus ICD consideration under the ACC/AHA/HRS arrhythmia guideline is what changes outcomes.
• Don't confuse the trypanosomes: T. cruzi (Americas, triatomine bug feces inoculated into the bite/mucosa, cardiac and GI disease) versus T. brucei (Africa, tsetse fly bite, sleeping sickness). Also distinguish Romaña sign from a chagoma.
• Screening pearl: US blood donations are screened for T. cruzi, and immunosuppression or transplantation in a seropositive host can trigger reactivation — test before immunosuppressing an at-risk patient.